导师风采
樊英
个人信息
Personal Information
- 性别：女
- 导师类型：硕士生导师
- 职称：主任医师
- 该职称任职时间：20180701
联系方式
Contact Information
- 所属院系：肿瘤医院
- 所属专业：肿瘤学
- 邮箱 : fanyingfy@medmail.com.cn
- 工作电话 : 01087788120
个人简介
Personal Profile
主任医师，硕士生导师。北京协和医学院临床医学八年制博士。擅长乳腺癌等实体肿瘤的内科治疗，长期致力于乳腺癌精准治疗和综合治疗及转化研究，具备了丰富的肿瘤内科临床及科研经验。主持及参与了多项国家自然科学基金青年基金、中华癌症基金会青年科研基金等国家级及省部级科研项目，同时参与多项国际、国内抗肿瘤新药临床试验。在 JAMA Oncology, Annals of Oncology, Journal of Clinical Oncology等国内外杂志上发表学术论文80余篇，影响因子总和＞40分；同时参与了多部肿瘤内科专业和科普书籍的编写。2008-2009年赴英国皇家马斯登医院及国家癌症研究所访问，2008年选派为国家药品食品监督管理局药审中心外聘专家。
团队简介
Team Profile
待补充更新
- 研究方向Research Directions
乳腺癌
- 在校研究生Current Graduate Students
硕士研究生 3 名，博士研究生 0 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | 细胞色素CYP2D6酶基因型于SERM类药物疗效差异的前瞻性随机对照研究 | 2017-09-01 —— 2023-08-01 | 4.25 | 主持者 | |
| 2 | 对比白蛋白紫杉醇联合卡铂与紫杉醇联合卡铂用于三阴性乳腺癌新辅助化疗疗效的前瞻性研究 | 2019-07-01 —— 2025-06-30 | 10.0 | 主持者 | |
| 3 | 吡咯替尼在HER2未扩增伴点突变的乳腺癌患者中治疗敏感性差异的机制研究 | 2022-01-01 —— 2025-12-31 | 78.0 | 参与在研的国家或省部级科研项目 | 参与者 |
| 4 | 唑来膦酸预防高危三阴性乳腺癌术后复发转移的前瞻性、多中心、随机III期临床研究 | 2015-06-01 —— 2023-05-31 | 60.0 | 参与者 | |
| 5 | 基于免疫微环境标记物预测依维莫司疗效的研究 | 2022-01-01 —— 2024-12-31 | 15.0 | 主持者 | |
| 6 | 动态定制化ctDNA 监测德曲妥珠单抗（T-DXd）联合吡咯替尼一线治疗HER2阳性晚期乳腺癌临床结局的研究 | 2023-12 —— 2025-11 | 50 | 主持在研的国家或省部级科研项目 | 主持人 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors | Frontiers in Oncology | 2022-10 | 樊英 |
| 2 | Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis. | Annals of Translational Medicine | 2021-01 | 樊英 |
| 3 | Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial. | JAMA Oncology. | 2021-10 | 樊英 |
| 4 | Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. | Annals of Oncology | 2013-05 | 樊英 |
| 5 | First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. | BMC Cancer | 2019-03 | 樊英 |
| 6 | Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy. | Scientific Reports | 2020-04 | 樊英 |
| 7 | Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtasine: a systemic review and meta-analysis. | Annals of Translational Medicine | 2021-07 | 樊英 |
| 8 | Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. | International Journal of Cancer | 2020-12 | 樊英 |
| 9 | The Prognostic Role of HuR Varies Between Different Subtypes of Breast Cancer Patients: Data Mining and Retrospective Analysis | Breast Cancer-targets and therapy | 2023-02 | 樊英 |
| 10 | Current Clinical Trials on Breast Cancer in China: A Systematic Literature Review. | Cancer | 2020-08 | 樊英 |
| 11 | Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer. | Medicine (Baltimore) | 2015-11 | 樊英 |
| 12 | Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/HumanEpidermal Growth Factor Receptor 2-negative Breast Cancer: A Single InstituteExperience of More Than 10 Years | Clinical Breast Cancer | 2018-12 | 樊英 |
| 13 | Hormonal therapy might be a better choice as maintenance treatment thancapecitabine after response to first-line capecitabine-based combinationchemotherapy for patients with hormone receptor-positive and HER2-negative,metastatic breast cancer. | Chinese Journal of Cancer Research | 2016-04 | 樊英 |
| 14 | Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis | Journal of Oncology | 2020-10 | 樊英 |
| 15 | Prospective study of vinorelbine and capecitabine combination therapy inChinese patients with metastatic breast cancer pretreated with anthracyclinesand taxanes. | Chemotherapy | 2010-08 | 樊英 |
| 16 | A retrospective study of metachronous and synchronous ipsilateral supraclavicular lymph node metastasesin breast cancer patients. | Breast | 2010-01 | 樊英 |
| 17 | Decreased serum HDL at initial diagnosis correlates with worse outcomes fortriple-negative breast cancer but not non-TNBCs. | International Journal of Biological Markers | 2015-05 | 樊英 |
| 18 | Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy | Cancer Management and Research | 2022-05-31 | 樊英 |
| 19 | Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China. | International Journal of Cancer | 2020-12 | 樊英 |
| 20 | CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care? | Lancet Oncology | 2021-01 | |
| 21 | Case Report: An Internal Mammary Rhabdomyosarcoma After Mastectomy and Systemic and Radiation Therapy in a Patient With Breast Cancer | Frontiers in Oncology | 2021-10 | 第一作者 |
| 22 | Efficacy of everolimus-based therapy in advanced triple-positive breast cancer: Experience from three cancer centers in China | Thoracic Cancer | 2023-11 | 第一作者 |
| 23 | Adjuvant treatment strategy evolution and risk stratifcation for hormone receptor-positive, human epidermal growth factor receptor-2 negative early breast cancer in China | The oncologist | 2024-05 | 第一作者 |
| 24 | CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis | BMC CANCER | 2023-08 | 第一作者 |
- 科研获奖Research Awards
| # | 获奖证书编号 | 奖项名称 | 获奖级别 | 获奖类别 | 获奖等级 | 获奖日期 | 颁奖单位 | 本单位是否为第一完成单位 | 完成单位排名 | 本人排序 | 备注 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 201503024P0807 | 中华医学科技奖 | 国家级 | 其他国家级奖励 | 三等奖 | 2015-12-21 | 中华医学会 | 是 | 1 | 1 | |
| 2 | 201501013P1507 | 华夏医学科技奖 | 国家级 | 其他国家级奖励 | 一等奖 | 2016-11-25 | 中国医疗保健国际交流促进会 | 是 | 1 | 1 | |
| 3 | 2015-257 | 科学技术进步奖 | 省部级 | 教育部高校科研成果奖（科学技术、人文社科） | 二等奖 | 2016-02-26 | 中华人民共和国教育部 | 是 | 1 | 7 | |
| 4 | 2021-K-A-10-06 | 妇幼健康科学技术奖 | 国家级 | 其他国家级奖励 | 一等奖 | 2021-09-06 | 妇幼健康研究会 | 是 | 1 | 1 | |
| 5 | K-1502-1-2-6 | 中国抗癌协会科技奖 | 省部级 | 其他省部级奖励 | 一等奖 | 2016-10-14 | 中国抗癌协会 | 是 | 1 | 1 |
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 作为主创人员获得授权的发明专利和新品种 | 一种预测乳腺癌对曲妥珠单抗联合化疗治疗敏感性的生物标记物 |
| 2 | 出版高水平专著 | 临床肿瘤内科手册 |
| 3 | 出版高水平专著 | 乳腺癌靶向治疗原则与实践 |
| 4 | 出版高水平专著 | 化学治疗所致恶心呕吐的护理指导 |